Thank you for submitting your manuscript for consideration by The EMBO Journal. I have now had the opportunity to read it carefully and to discuss it with the other members of our editorial team. I am afraid that the outcome of these discussions is not a positive one.
Thank you for submitting your manuscript for consideration by The EMBO Journal. I have now had the opportunity to read it carefully and to discuss it with the other members of our editorial team. I am afraid that the outcome of these discussions is not a positive one.
We appreciate that you were able to identify TOR1 as a novel interaction partner for the cauliflower mosaic virus TAV protein, to map the interaction and to provide evidence that this interaction is required for TAV activity in translation reinitiation of viral polycistronic mRNAs. Your data further suggest that TAV induces TOR and S6K1 (hyper)activation, TOR/S6K1-dependent phosphorylation of RISP and formation of reinitiation competent ribosome complexes. However, it is known that TAV induces translation reinitiation of viral polycistronic mRNAs, that it interacts with translation initiation complexes and that RISP binds to TAV and initiation complexes and enhances TAV function. Furthermore, the recruitment of TOR/S6K1 to translation initiation complexes and their involvement in regulating translation initiation is known, albeit not in the context of reinitiation. Clearly, we recognise that here you were able to provide evidence for a physical interaction between TAV and TOR and for a requirement of TOR/S6K1 in TAV-induced translation reinitiation for the first time. Still, if one looks at the study from a more general conceptual perspective we do not think that the extent of novel biological and mechanistic insight provided by the study reaches the level required for publication in The EMBO Journal. We have thus decided not to send out the paper for Thank-you very much for all the discussion you have had with colleagues concerning our paper.
However, I would strengthen here that we uncover a link between the TOR signalling pathway and reinitiation after translation of a long ORF (a translation initiation mechanism that is normally silenced in eukaryotes). Cellular mechanisms restricting reinitiation capacity in eukaryotes have remained a long-standing unresolved question in the field of protein synthesis. As you have seen we found a key to their activation while studying the translation strategies of a plant virus that is able to overcome cellular barriers to reinitiation. We have identified TOR as being essential to successful reinitiation of the polycistronic translation mechanism used in this plant virus, thereby uncovering a first case of a direct viral control of the TOR pathway. This is a major step forward in our understanding of the reinitiation mechanism promoted by TAV, rather than just an incremental improvement on what was known before. Moreover, our results indicate a novel general role for TOR in translation re-initiation, in addition to its known function as a factor activating canonical translation in eukaryotes.
Our studies on this exceptional case of polycistronic translation in eukaryotes are driven by the wish to address a long-standing general question: why do such events not generally occur in mRNA translation, and what is the mechanism that promotes reinitiation in this rather exceptional case? We discover here that TAV provokes constitutive activation of TOR signalling, as manifested by phosphorylation of S6K1. In addition we reveal details in the mechanism of TOR function in reinitiation after a long ORF translation and provide an answer to the question of how TOR can promote reinitiationóupon activation TOR associates with polysomes to ensure de novo phosphorylation of its novel target RISP. We identified such a novel TOR phosphorylation targetóRISPóin plants; RISP is phosphorylated at S267 via the TOR/S6K1 signalling pathway on polysomes to render ribosomal complexes reinitiation-competent.
Thus, we uncover that reinitiation would require re-phosphorylation of factors that are recruited during the first initiation event at the ORF. This requirement for a specific protein TAV with the property of binding to TOR for its constitutive activation can explain why reinitiation events after translation of a long ORF do not generally occur in eukaryotes. Indeed, we detected striking difference in TOR phosphorylation levels between wild type and TOR-overexpressing plants. Still, if one looks at the study from a more general conceptual perspective we think that the extent provided by our study for a future research will be requirements for TOR in reinitiation after a short ORF (sORF) translation. Reinitiation after sORF translation is a common phenomenon in eukaryotes (especially in plants), where sORFs are important regulators involved in the control of expression of genes encoding potent proteins such as cytokines, growth factors, protein kinases, and transcription factors. Several disorders in humans, for example hereditary thrombocythemia, are due to perturbation of such regulation. TOR can be a very important regulator of reinitiation efficiency.
We belief that offering substantial new insights into the mechanism whereby TOR promotes re-initiation, and our results will certainly be of great general interest to anyone working in the field of eukaryotic translation (our reviewers) and general readers. Thus, we hope that you re-consider our paper for publication in EMBO J.
I look forward to hearing from you.
Appeal considered 04 August 2010
Thank you for your letter asking us to reconsider our decision on your manuscript. Let me first of all apologise for the delay in getting back to you with a reply. I was not on the office and only returned this week. In the meantime, I have now had a chance to review your arguments and to consult with an external editorial advisor of suitable expertise who knows both the topic and the journal very well. We have come to the conclusion that we have no objection to seeking advice from referees; but I am sure you appreciate the fact that we cannot predict the outcome of the review process.
I will be in touch again as soon as I hear back from the referees.
Yours sincerely,
Editor
The EMBO Journal Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by three referees whose comments are shown below. As you will see while referee 1 is more positive the other referees express hesitations regarding publication of the paper here. I will not repeat all their individual points of criticism here, but referee 2 feels strongly that the functional significance of your findings in the reinitiation mechanism needs to be addressed in considerably more depth. Referee 3 raises major concerns regarding key aspects of the experimental evidence provided which in his/her view preclude publication of the study here at this point. Clearly, both of these issues (deeper mechanistic insight as well as conclusiveness of the data) go well beyond both the scope and the time frame of a single revision (3 months) and it is our policy to allow a single round of revision only. Furthermore, the outcome of the additional required experiments cannot be predicted at this point. In such a situation, I am afraid to say that we cannot consider a revision.
Please note that we receive many more submissions at The EMBO Journal than we can possibly publish, and that we can only accept those very few manuscripts, which are met with strong and enthusiastic support from at least a majority of reviewers upon initial review. As unfortunately this is not the case for the present submission, I am afraid to say that I see little choice but to come to the conclusion that we cannot offer to publish the manuscript.
Thank you in any case for the opportunity to consider this manuscript. I am sorry we cannot be more positive on this occasion, but we hope nevertheless that you will find our referees' comments helpful.
The EMBO Journal
Referee #1 (Remarks to the Author):
In this paper the authors describe a new protein that interacts with the CaMV TAV and is necessary for TAV function. This is a substantial addition to the literature on how the TAV alters ribosomes for polycistronic expression. However, I thought that the paper lacked some details. I summarize three areas below.
1. The authors state that CaMV was unable to infect the 35-7 plants and in the Supplementary Materials and Methods they provide information about the infectivity assays. I have four concerns about this test.
a. In Fig. 2B , expression of TOR mRNA in line 35-7 is listed as 10% of the overexpressing line G548. I think, though, that the wild type should be set to 100% and other expression levels adjusted accordingly. The authors obtained this line from Deprost et al., (2007) , and in that paper Deprost said that TOR expression was only 50% of the wild type plants.
b. The authors state that TOR was very low or not detectable in plants selected for the infectivity assay. How does this relate to expression levels previously reported (i.e. 50% decrease for Deprost and 10% of the overexpressing line in this manuscript)? The significance of the western blot is unclear, without some knowledge on the quality of the antiserum.
c. The infectivity test ended at 14 dpi. CaMV infections are slower than viruses such as tobacco mosaic virus. In Fig. 4B , the authors own evidence shows that CaMV was not detectable in wild type plants until 10 dpi, so I think it is premature to end the test at 14 dpi. It could be that the infection might be delayed rather than abolished. Although the end points for infectivity tests are a subjective decision, I think that the test should be allowed to go until 21 or 28 dpi. There is a difference between a claim of "infection abolished" versus "infection delayed". 2. In supplementary Fig. 1A , the authors present evidence for co-localization of TAV and TOR. What was the percentage of colocalization of TAV and TOR? When evidence for co-localization is restricted to a single inclusion body, it is not possible to assess affinity of TOR for the TAV inclusions in vivo. It would be good to know whether colocalization was a relatively rare event in vivo (less than 5% of inclusions), or if it was very common. I do not think that this knowledge would change the outcome of the paper, but it does provide an important framework for assessing the utility of this assay.
3. In their model presented in the Discussion and in Fig. 7 , the authors suggest that TAV "can promote translation of consecutive multiple long ORFs on the same RNA" (illustrated with CaMV ORFs I and II in Fig. 7 ). The issue that I have with this statement is that most work that I am aware of in this paper and others has involved the construct pbiGUS, which consists of sORF VII, which has in the first position a small open reading frame that is essential but does not have a defined function and GUS in the second position. Many years ago some work was done concerning splicing of the 35S RNA that would have examined expression of ORF II. It would be interesting to know how effective the author's system is for reinitiation of expression of ORFII after sORF VII and ORFI. Can the TAV direct a high level of expression of ORFII, as illustrated in Fig. 7 , or is this model based on experimental evidence obtained with pbiGUS? I would like the authors to address this question in their discussion. If the experimental evidence is based mainly on pbiGUS, then perhaps this should be the bicistronic mRNA presented in Fig. 7 .
Other points.
Pg. 16. Change "How is to activate ..." to "How does the TAV activate ..."
Pg. 21. The authors state that the source of anti-3IF3c antibodies was K. Browning (Austin University). Do they mean the University of Texas, Austin TX?
Referee #2 (Remarks to the Author):
This paper concerns the role of the signalling pathway involving the target of rapamycin, TOR, and its substrate, S6 kinase, S6K, in the reinitiation of mRNA translation following the translation of a long open reading-frame or ORF. The particular case under study is that of the mRNA from the plant virus cauliflower mosaic virus (CaMV). This virus encodes a translation reinitiation factor, also called viroplasmin (TAV). TAV is already known to interact physically with components of the host cell translation machinery -the g subunit of eIF3, the large ribosome subunit protein L24 and RISP, 'reinitiation-supporting protein'.
The authors provide data that TAV interacts with TOR and that TOR activates S6K, which then phosphorylates RISP, promoting reinitiation. The authors' attention is drawn to a number of points.
MAJOR POINTS
1. This paper presents novel and potentially interesting data. Its major limitation is that the new findings do not address the mechanism of reinitiation and how the present data contribute to understanding this. Furthermore, the actual functional significance of the phosphorylation of RISP by S6K1 on S267 is not addressed, e.g., by testing the functional significance of this event using e.g., the S267A mutant.
2. In several places, where results rely on western blotting, findings from several independent experiments should be quantitated and the data presented with statistical analysis.
OTHER POINTS 1. Fig. 1 : the organisation of this figure is confusing as it is not clear which items of data really belong to which panel. It should be divided into more panels: as it stands, it is hard to work out which data are being discussed where and even whether all the data is actually discussed in the text.
2. P. 7, line 6 up: T389 is not the initiating phosphorylation event in the activation of mammalian S6K -there are other phosphorylation sites in its C-terminus which are probably phosphorylated earlier and certainly independently of T389.
3. P. 8, last two lines: it is actually now clear that T2448 in mammalian TOR is phosphorylated by S6K so its state of phosphorylation really reflects S6K activity, not TOR activity per se. This being so, why is there no signal for P-TOR in the G548 lane in Fig. 2D , although S6K1 seems to be active?
4. P. 9, lines 7-9: the authors cannot rule out that T449 is actually phosphorylated by another kinase that is activated by TOR (and there are several in mammalian cells, likely also in plants).
5. P. 11, I could not find where the data in the bottom left part of Fig. 3 are discussed.
6. P. 12, first line: isn't it possible that deficiency of TOR, a major regulator of cell function, affects viral replication through more than one mechanism, not just the one studied here?
7. P. 13, line 7: should be Fig. 5E not 6E
8. P. 14, last part: In Fig. 6E , the binding of the TAV mutant to RISP actually seems greatly decreased compared with WT TAV 9. P. 18 top part: the section about PP2A is pure speculation, is not necessary and should be removed. The same applies to the following comments about TAV and Rheb, although it is clearly interesting to study how TAV activates TOR.
10. P. 19, line 2: what does the comment about 'LR and MS unpublished data' refer to? More explanation is needed or this should be removed.
11. P. 18, line 9: does any subunit of eIF3 contain a consensus phosphorylation sequence for S6K?
12. The standard of the English needs to be improved, especially in the Discussion section.
Referee #3 (Remarks to the Author):
The overriding question underlying this work is: How is the genome of a plant pararetrovirus, such as cauliflower mosaic virus (CaMV), expressed? Two mRNA species are generated following CaMV infection: a 19S mRNA encoding the ORF VI product, the so-called transactivator (TAV); and a 35S mRNA representing the whole genome. The 35S mRNA is structurally polycistronic, as follows: 5' -ORF VII (only ~100 codons) -ORF I -ORF II -ORF III -ORF IV (equivalent to retroviral gag i.e. the coat protein) -ORF V (reverse transcriptase, protease, RNase-H) -ORF VI (TAV). The products of ORFs I-III are involved in insect transmission and cell-cell transmission of the virus, and so are required for (natural) infection leading to the development of the chlorotic lesions visible in Fig. 4A . However, these products are not needed for infection of protoplasts, which requires only the ORF IV and ORF V products. The crux of the problem is that TAV is required for infectivity, although in the case of protoplast infection TAV can be replaced by expressing gag/coat protein (ORF IV) and reverse transcriptase (ORF V) in trans (as in Fig. 1C ). Because no sub-genomic RNAs have been identified, it has long been considered that the 35S mRNA must be translated as a polycistronic mRNA, although one wonders if the search for possible sub-genomic mRNAs was as stringent and as sensitive as is now demanded of claims for cellular mRNA IRESs. Certainly, there is a paper from the Hohn group showing that there is actually some splicing to a 3'-splice acceptor site in ORF II (from 4 different 5'-splice donor sites), and that such splicing is even essential for infectivity (EMBO J. 14, 3552, 1995) . Moreover, this paper stresses that it only searched for splice sites in a limited region of the 35S mRNA, and so it remains an open question whether there aren't other spliced forms that are essential for infectivity -a possibility which has never been pursued further as far as I am aware. Nevertheless the working hypothesis is that the downstream ORFs in the 35S mRNA are translated from polycistronic mRNAs (which is unprecedented in eukaryotic systems), and that this exceptional behaviour is dependent on TAV. Support for this hypothesis comes from the fact that transfection of a bicistronic construct into plant protoplasts does not result in expression of the downstream cistron unless TAV is co-expressed. These assays seem to have invariably used a bicistronic construct consisting of the CaMV ORF VII and the short (~ 60 nt) ORF VII-ORF I non-translated linker fused to a CAT ORF reporter in the first experiments, and more recently to a GUS ORF (as in Fig. 3B ). In view of the rather short length of both ORF VII (~100 codons) and the ORF VII -ORF I linker, one wonders to what extent any reinitiation occurring on this test bicistronic mRNA is typical of what might be happening at all the other intercistronic junctions in the 35S mRNA. Certainly, when the ORF VII upstream cistron of an ORF VII-CAT bicistronic mRNA was replaced by a complete GUS ORF plus some GUS 3'-UTR sequences, CAT expression was reduced by at least 10-fold (Bonneville et al. 1993 ref) , implying that the putative reinitiation efficiency is strongly influenced by the length or the actual sequences of either the upstream cistron, or the intercistronic non-translated spacer. Another problem with this assay, in its usual form (ORF VII -GUS, or CAT), is that, to my knowledge, the absolute efficiency of reinitiation (as would be shown by the molar ratio of the ORF VII product to the GUS/CAT product) has never been determined. This question of efficiency of reinitiation is important when one considers how reinitiation might operate on the intact 35S mRNA, where no less than 5 reinitiation events would be required, and where it seems highly unlikely that the 6 proteins encoded by the 35S mRNA will be synthesised in equimolar amounts. For example, by analogy with mammalian retroviruses, one would expect the ORF IV product (gag , or coat protein) to be expressed in very much higher amounts than the ORF V product (reverse transcriptase), again implying that efficiency of the putative reinitiation event could be influenced by sequences at or around the intercistronic junction.
Another problematic feature is that TAV is an abbreviation for "transactivator/viroplasmin", and the second part of this designation is due to the fact that TAV is the major component of inclusion bodies, or foci, found in infected cells. These foci are thought to be where virion assembly takes place, and possibly viral DNA synthesis, but is it really possible that the translation of viral 35S mRNA could actually take place in, or on, what are basically inclusion bodies? It would be interesting to know what proportion of the TAV is in inclusion bodies, and how much is "monomeric", but this information does not seem to be available. . From these interaction studies, and from investigating how mutations in these interaction sites affect the level of transactivation, some rather complex models (e.g. Fig. 7 of this manuscript) of how TAV's interactions with RISP, eIF3 and 60S ribosomal subunits could potentiate translation reinitiation on polycistronic mRNAs. Whilst these models are reasonably consistent with the observations, they make numerous presumptions which go far, far beyond what the data actually show. In particular, there is almost no evidence whatsoever for all the rearrangements of the interactions between proteins and ribosomal subunits proposed in these models. The work described in this manuscript is a continuation of this same approach. Using GST pulldowns and yeast two-hybrid assays (Fig. 1A , 1B), it shows that TOR (specifically the N-terminal half of TOR) interacts with the MAV region of TAV, specifically the dsR region (so named because it has homology to some dsRNA binding proteins). Small deletions in MAV dsR, which abrogate the interaction. abolish transactivation in the protoplast infectivity assay (Fig. 1C) . Overexpression of TAV (in the AT7 line) promotes phosphorylation of TOR and of its downstream target, S6 kinase 1 (Fig. 2C, 2D ), and this S6K1 phosphorylation is largely (but not completely) negated by deleting the dsR region from the over-expressed TAV (Fig. 2E ). Increased S6K phosphorylation is also seen in infected plants, but is only convincing at late stages, 14 days post-inoculation (Fig. 2G ).
Immunoprecipitations show that over-expressed TAV promotes association of TOR with TAV and with RISP, but not if the dsR region of TAV has been deleted ( Fig. 2F) . However, the association of eIF3 with TAV and with RISP seems to be unaffected by the presence or absence of the dsR region in the over-expressed TAV (Fig. 2F ).
Turning to the more direct functional assays using the bicistronic construct ( Fig. 3B ), TAV overexpression stimulates downstream cistron translation by ~20-fold. This stimulation is doubled by co-expressing TOR, which also sharply increases the level of S6K1 phosphorylation, with both effects absent when a non-phosphorylatable TOR mutant is tested. As mentioned above, a serious deficiency of these assays is that we have no idea of the efficiency of the putative reinitiation event, i.e. no idea of the relative molar yield of the upstream ORF VII product and the downstream GUS product. In addition, although the data show no change in mRNA levels ( Fig. 3B ), these appear to have been determined by using RT-qPCR to look at a 3'-terminal part of the GUS cistron, which leaves open the question that so often arises with work on IRESs -namely is all the mRNA still bicistronic?
Other functional assays are shown in Fig. 4 . A plant cell line (35-7) with reduced TOR levels appears to be immune (at least in the 14 day test period) to CaMV infection (Fig. 4A) , and protoplasts derived from such plants show no TAV-dependent activation of downstream cistron translation using the bicistronic mRNA assay (Fig. 4C ). However, this assay in Fig. 4C used only half as much TAV-expression plasmid as that in Fig. 3B . Could transactivation be rescued in 35-7 protoplasts by introducing more TAV?
Last, Figs 5 and 6 are largely concerned with co-sedimentation (in sucrose gradients) of TAV, TOR, RISP and eIF3 with ribosomes/polysomes, and to my mind this is the least satisfactory part of the whole manuscript. In ribosome/polysome profiles from AT7 plants which over-express TAV, there is reasonable co-sedimentation of TAV, eIF3 and RISP, but the distribution of TOR in the gradient seems rather different (Fig. 5D) , contrary to what the authors seem to claim. In plants overexpressing TAV that lacks the critical dsR region the sedimentation profiles are a little different (Fig 5E) , in that there is less polysome association of these proteins, except in the case of RISP.
However, in what appears to be essentially the same experiment (Fig. 6F) , the distribution of TAV in the gradient is completely different from that in Figs 5D and 5E, and yet there seems to be no explanation or reason given in the manuscript for why there should be this difference. This is a serious discrepancy because it throws doubt on the reproducibility of these co-sedimentation experiments, and therefore raises doubts as to the validity of any conclusions derived from them.
For what it is worth, RISP is found in two places in these Fig. 6F gradients: (i) in the 80S region if wild-type TAV is being overexpressed, or in lighter fractions if it is TAV with the dsR deletion, and (ii) in polysomes irrespective of which form of TAV is overexpressed. Phosphorylated RISP, however, is only found in polysomes with wild-type TAV overexpression, with some at the top of the gradient with either form of TAV overexpressed.
The rest of Figure 6 shows that RISP phosphorylation is stimulated by co-expression of wild-type TAV (in AT7 plants), but there is still some basal phosphorylation in the presence of dsR-deleted TAV (Fig. 6C, 6D) ; and that in yeast two hybrid assays RISP interacts directly with S6K1, but not with the TAV dsR region (Fig. 6E ), in agreement with the Thiebeauld et al (2009) paper which showed RISP interacting with a TAV site slightly downstream of the dsR region. The implication is that it is TAV-associated TOR that phosphorylates and so activates S6K1, and it is activated S6K1 that actually phosphorylates RISP.
SUMMARY
This manuscript has a great deal of detail that cannot be faulted concerning the interactions of TOR, TAV, RISP and eIF3, and on the phosphorylation of S6K1 by TAV-associated TOR. There are some problems associated with the functional assays of Figs 3 and 4, which need attention. However, by far the most serious problem is the apparent inconsistency in the sucrose density gradient distributions of (especially) TAV in Figs 5D, E as compared with Fig. 6F . This inconsistency makes the manuscript UNACCEPTABLE in its present form, because it threatens to undermine the credibility of the whole work, or at least all the work on association of TAV, TOR etc with ribosomes/polysomes.
The other problem is with the model presented in Fig. 7 (and described in the Discussion), in respect of all the rearrangements of the interacting partners that are proposed in this model. There is very little direct evidence for these rearrangements -in fact, I would go so far as to say, not a shred of evidence. Therefore I think it ESSENTIAL that the authors preface the description of the model with the reservations that although the model is not inconsistent with the data, there is no direct evidence for all the proposed rearrangements, and that the model should therefore be considered highly speculative. Without this strong "health warning" there is a risk that the average reader will accept the model as the gospel truth, without realising the enormous gap between what the evidence actually shows and what the model is proposing. In fact this has already happened in the past: earlier versions of this model have been included in reviews as though they were fact, and without any hint as to what is the evidence on which they were based, and what this evidence actually shows. We presented western blot analysis of TOR levels in wild type and mutant plants in Fig. 2D . According to the suggestion of reviewer 1, we set the TOR levels in wild type plants to 100%. western blot analysis was not performed in Deprost's paper. Our TOR quality antiserum was tested on recombinant Arabidopsis TOR produced in E. coli and compared with that of commercially available anti-mTOR antibodies. Both anti-TOR antibodies provided a similar ratio between TOR levels in wild type and selected 35-7 plants.
It is very important to note that for this experiment we selected those 35-7 RNAi silenced plants that displayed the serrated and pointed leaf phenotype (see FigS2B). These plants are characterized by about 15% or non-detectable TOR levels compared to those in wild type plants under our conditions (Fig. 2D or Fig. 4C ).
However, we now include TOR mRNA analysis data in Fig. 4 as part C. RT-qPCR revealed that TOR mRNA levels were about 10% of wild type in selected RNAi silenced 35-7 plants (data now included in Fig. 4C ).
The discrepancy between TOR mRNA levels in 35-7 plants (50% in Deprost and 10% in our manuscript; see new Fig. 4C ) can be explained by the fact that we selected mutant plants according to the particular phenotype referred to above.
c. The infectivity test ended at 14 dpi. CaMV infections are slower than viruses such as tobacco mosaic virus. In Fig. 4B The infectivity studies were done at least in two independent experiments each with 10 or more selected plants. These data are now presented. Fig. 7 .
Our experiments in plant protoplasts were made with biGUS, which contains CaMV ORFVII and a GUS ORF. According to reviewer 1's suggestion, unrelated ORFs 1 and 2 are replaced by ORFVII and the GUS ORF used in this study (see Fig. 7 ).
The minor points raised by this reviewer have been addressed as follows: First of all, our data show that we have identified a novel and essential player in reinitiation of translation. According to our results, activation of the TOR signalling pathway is required for translation of the second ORF of a bicistronic RNA. Earlier we suggested a mechanism in which some essential initiation factors are re-used for the re-initiation event, and proposed a model of how these factors (reinitiation-supporting factors) are retained on translating ribosomes during the elongation step of protein biosynthesis (Park et al., 2001 ).
(1) In this manuscript, we present evidence that, in addition to recruitment of some eIFs to polysomes, their activation via phosphorylation may be also required. We show that the TOR pathway plays a role in phosphorylation of RISP, most likely in polysomes, and show that it is essential for the transactivation function of TAV. According to reviewer 2's suggestion, we have compared the interaction capacity of the RISP-S267A mutant with previously identified partners of RISP. The results suggest that phosphorylation possibly alters the binding affinity of RISP for either eIF3 or TAV.
(2) We include additional data that speak in favour of our model proposed in 2001: dissociation of polysomes on 40S and 60S subunits revealed some association of eIF3 and RISP with the 60S fraction in the presence of TAV, which supports our hypothesis on relocation of these factors to 60S by TAV.
We believe that all these results combine to make a significant impact on our understanding of the protein factors that are required to assist TAV in activating reinitiation after long ORF translation in plants.
In several places, where results rely on western blotting, findings from several independent experiments should be quantitated and the data presented with statistical analysis.
Quantification data are provided now as Supplementary data, see Supplementary Figs . S2 and S5.
The minor points raised by this reviewer have been addressed as follows:
Fig. 1: the organisation of this figure is confusing as it is not clear which items of data really belong to which panel. It should be divided into more panels: as it stands, it is hard to work out which data are being discussed where and even whether all the data is actually discussed in the text.
The Fig. was modified by sub-dividing it into more panels. Discussion of the data obtained has been improved.
P. 7, line 6 up: T389 is not the initiating phosphorylation event in the activation of mammalian S6K -there are other phosphorylation sites in its C-terminus which are probably phosphorylated earlier and certainly independently of T389.
The mistake was corrected (P. 8) Fig. 2D , although S6K1 seems to be active?
P. 8, last two lines: it is actually now clear that T2448 in mammalian TOR is phosphorylated by S6K so its state of phosphorylation really reflects S6K activity, not TOR activity per se. This being so, why is there no signal for P-TOR in the G548 lane in
Perhaps back phosphorylation of TOR by activated S6K1 is modulated or less efficient in plants, and thus below the limit of detection of anti-mTOR antibodies (the signal from anti-S6K1-P antibodies in TAV transgenic plants is more than two-fold higher than that in G548 plants).
P. 9, lines 7-9: the authors cannot rule out that T449 is actually phosphorylated by another kinase that is activated by TOR (and there are several in mammalian cells, likely also in plants).
This sentence was corrected (P. 9)
P. 11, I could not find where the data in the bottom left part of Fig. 3 are discussed.
This part of Fig. 3 is better organized and the discussion has been improved
P. 12, first line: isn't it possible that deficiency of TOR, a major regulator of cell function, affects viral replication through more than one mechanism, not just the one studied here?
TAV has an essential function in the nucleus of infected cells. We assume that TOR may support transcription of the 8 kpb 35S pregenomic RNA by Pol II.
P. 13, line 7: should be Fig. 5E not 6E
The mistake was corrected
P. 14, last part: In Fig. 6E, the binding of the TAV mutant to RISP actually seems greatly decreased compared with WT TAV
Binding of RISP to either TAV or TAV dsR now is quantified and presented in Fig. 6E .
P. 18 top part: the section about PP2A is pure speculation, is not necessary and should be removed. The same applies to the following comments about TAV and Rheb, although it is clearly interesting to study how TAV activates TOR.
Both paragraphs have been removed
P. 19, line 2: what does the comment about 'LR and MS unpublished data' refer to? More explanation is needed or this should be removed.
Comment was removed
P. 18, line 9: does any subunit of eIF3 contain a consensus phosphorylation sequence for S6K?
RxRxxS/T can be found in Arabidopsis eIF3 subunits b, c, f, h and i 12. The standard of the English needs to be improved, especially in the Discussion section. This was improved Reviewer #3
The overriding question underlying this work is: How is the genome of a plant pararetrovirus, such as cauliflower mosaic virus (CaMV), expressed?
Actually, we aimed to study the mechanism of CaMV TAV function in activation of reinitiation after long ORF translation. We have identified TAV partners among cellular proteins that are required for TAV transactivation function and aim to study their role in reinitiation as well. Since TAV alone transactivates reinitiation of an artificial bicistronic messages (F¸tterer and Hohn, NAR 20, 1992) , we use the partially artificial construct biGUS, described and characterized in Bonneville et al. (Cell 59, 1989 
These assays seem to have invariably used a bicistronic construct consisting of the CaMV ORF VII and the short (~ 60 nt) ORF VII-ORF I non-translated linker fused to a CAT ORF reporter in the first experiments, and more recently to a GUS ORF (as in Fig. 3B). In view of the rather short length of both ORF VII (~100 codons) and the ORF VII -ORF I linker, one wonders to what extent any reinitiation occurring on this test bicistronic mRNA is typical of what might be happening at all the other intercistronic junctions in the 35S mRNA. Certainly, when the ORF VII upstream cistron of an ORF VII-CAT bicistronic mRNA was replaced by a complete GUS ORF plus some GUS 3'-UTR sequences, CAT expression was reduced by at least 10-fold (Bonneville et al. 1993 ref), implying that the putative reinitiation efficiency is strongly influenced by the length or the actual sequences of either the upstream cistron, or the intercistronic non-translated spacer. Another problem with this assay, in its usual form (ORF VII -GUS, or CAT), is that, to my knowledge, the absolute efficiency of reinitiation (as would be shown by the molar ratio of the ORF VII product to the GUS/CAT product) has never been determined.
In our experiments to study the effects of TAV-interacting partners on transactivation we used a well-known and previously described reporter ó pbiGUS. Although CaMV ORF VII is relatively short, it fully blocks downstream expression of GUS ORF, which correlates well with other results in plants and mammals showing that shorter ORFs (about 100 nt) can abolish reinitiation of a downstream ORF. GUS ORF expression in biGUS is activated only upon overexpression of TAV, but not other proteins (more than 10 different proteins were investigated; see references from the Hohn laboratory cited above).
Some questions of reviewer 3
Some experiments to estimate efficiency of GUS ORF expression from biGUS have been carried out previously:
(1) The reinitiation efficiency in biGUS was compared with initiation efficiency of the biGUS monocistronic deletion derivative monoGUS (Bonneville et al., 1989) . Strikingly, reinitiation efficiency was only four fold lower than cap-dependent initiation (data were normalized to GUS RNA levels).
(2) It was shown that TAV transactivation efficiency in plant protoplasts depends neither on the size of the upstream ORF nor on the distance between the ORFs (max length investigated was 600 nt) to be translated (F¸tterer and Hohn 1991; 1992) . Although the reinitiation efficiency of the GUS-CAT bicistronic construct is lower than that of VII-CAT, it is greatly increased in the presence of an additional sORF in front of the GUS ORF (Fütterer and Hohn, EMBO J. 10, 1991) . This would be a very interesting subject for further study. 49, 1990) . Here, up to 5 reinitiation events within several reporter gene fusions to the start codons of ORFs I to VII were analysed in plant protoplasts. Reporter gene fusions to ORFs I, II, III, IV, and V did not rise to any substantial activity, while their cotransfection with the TAV plasmid gave rise to the following activities VII::CAT (100%), VII-I::CAT (100%), VII-I-II::GUS (51%), VII-I-II-III::GUS (33%), VII-I-II-III-IV::CAT (50%), I-II-III-IV-V::GUS (3%). ORFIV expression was clearly 10-fold higher compared to expression of the Pol ORF. Obviously, it would be of great interest to study why reinitiation at Pol ORF is less efficient than at ORFIV, but that was not the subject of this study.
Another problematic feature is that TAV is an abbreviation for "transactivator/viroplasmin", and the second part of this designation is due to the fact that TAV is the major component of inclusion bodies, or foci, found in infected cells. These foci are thought to be where virion assembly takes place, and possibly viral DNA synthesis, but is it really possible that the translation of viral 35S mRNA could actually take place in, or on, what are basically inclusion bodies? It would be interesting to know what proportion of the TAV is in inclusion bodies, and how much is "monomeric", but this information does not seem to be available.
It has been suggested that, at later stages of viral infection, the proportion of TAV in inclusion bodies can rise to up to 95% (Haas at al., 2008)
Whilst these models are reasonably consistent with the observations, they make numerous presumptions which go far, far beyond what the data actually show. In particular, there is almost no evidence whatsoever for all the rearrangements of the interactions between proteins and ribosomal subunits proposed in these models.
Our earlier model stated that TAV/eIF3 can travel with 80S during the elongation step through relocation of TAV/eIF3 to the back of the 60S subunit via interaction between TAV and L18 (Park et al., Cell, 2001) . (Localization of L13 on the eukaryotic 60S ribosome subunit is not known).
Apparently, the main concern for reviewer 3 in our model is the rearrangement of TAV-binding partners to the rear side of 60S during elongation. We have now included an additional sucrose gradient experiment, in which attachment of eIF3 and RISP to 60S can be seen in TAV-containing polysomes after their EDTA-dependent dissociation. See new Fig.  5H .
As mentioned above, a serious deficiency of these assays is that we have no idea of the efficiency of the putative reinitiation event, i.e. no idea of the relative molar yield of the upstream ORF VII product and the downstream GUS product. In addition, although the data show no change in mRNA levels (Fig. 3B), these appear to have been determined by using RT-qPCR to look at a 3'-terminal part of the GUS cistron, which leaves open the question that so often arises with work on IRESs -namely is all the mRNA still bicistronic?
See above, and we have included absolute values of GUS functional activity in the experiments shown in Figs. 3 and 4 (See Fig. legends) . GUS ORF in pbiGUS is not leaky in protoplasts until TAV is provided, suggesting that there is no degradation, and no translation from internally cleaved transcripts without TAV. TAV was not characterized as inducing any RNA degradation.
We saw no significant differences in RNA levels as measured by RT-qPCR. The length of transcripts was verified by semi-quantitative PCR (data not shown), and we did not find any significant differences in the levels of full-length transcripts.
Other functional assays are shown in Fig. 4 (Fig. 4A) , and protoplasts derived from such plants show no TAV-dependent activation of downstream cistron translation using the bicistronic mRNA assay (Fig. 4C) . However, this assay in Fig.  4C used only half as much TAV-expression plasmid as that in Fig. 3B (Fig. 5D) , contrary to what the authors seem to claim.
. A plant cell line (35-7) with reduced TOR levels appears to be immune (at least in the 14 day test period) to CaMV infection
Indeed, the distribution of TOR in the gradient differs from the distribution of TAV, eIF3 and RISP. We claim that TAV binding to TOR mediates TOR activation. Binding of activated TOR to polysomes may proceed without TAV assistance. See Discussion section.
However, in what appears to be essentially the same experiment (Fig. 6F) ,
the distribution of TAV in the gradient is completely different from that in Figs 5D and 5E, and yet there seems to be no explanation or reason given in the manuscript for why there should be this difference. This is a serious discrepancy because it throws doubt on the reproducibility of these co-sedimentation experiments, and therefore raises doubts as to the validity of any conclusions derived from them.
We repeated the isolation of polysomes and their analysis by western blot. Polysomes are now better resolved (see Supplementary Materials and methods). Our main result is that the amount of RISP-P/ RISP in polysomes is close to zero. However, RISP-P is seen in monosomes.
For what it is worth, RISP is found in two places in these Fig. 6F gradients: (i) in the 80S region if wild-type TAV is being overexpressed, or in lighter fractions if it is TAV with the dsR deletion, and (ii) in polysomes irrespective of which form of TAV is overexpressed. Phosphorylated RISP, however, is only found in polysomes with wild-type TAV overexpression, with some at the top of the gradient with either form of TAV overexpressed.
RISP seems to be present in monosomes with either TAV or TAV dsR, while we do not usually see it in wild type plants.
The rest of Figure 6 shows that RISP phosphorylation is stimulated by co-expression of wild-type TAV (in AT7 plants), but there is still some basal phosphorylation in the presence of dsR-deleted TAV (Fig. 6C, 6D) ; and that in yeast two hybrid assays RISP interacts directly with S6K1, but not with the TAV dsR region (Fig. 6E ), in agreement with the Thiebeauld et al (2009) paper which showed RISP interacting with a TAV site slightly downstream of the dsR region.
OK

The implication is that it is TAV-associated TOR that phosphorylates and so activates S6K1, and it is activated S6K1 that actually phosphorylates RISP.
This is difficult to say: either TAV-associated TOR or TOR already activated by TAV phosphorylates S6K1, which then phosphorylates RISP
The other problem is with the model presented in Fig. 7 We do not agree that our model is not consistent with the data. This model was proposed in 2001, where, to explain how eIF3 attached to polysomes during the long elongation event, we proposed its relocation from 40S to 60S via TAV binding to the rear side of 60S (L18).
We have now decided to include in the present manuscript data that we had originally to publish elsewhere. We show that, even after dissociation of polysomes by EDTA to 40S and 60S, eIF3 and RISP are seen co-sedimenting with the 60S fraction in addition to 40S in the presence of TAV.
In addition, we have simplified our discussion of how TOR participates in activation of polycistronic translation
Page 8, line 10. Should be Fig. 2C (not 3C ).
This mistake was corrected
Page 12, line 1. Since RISP was only discovered in 2009 , Park et al, 2001 is an inappropriate reference here -or at least it is not a sufficient reference since it only examines eIF3.
Since we are talking here about eIF3 and RISP, both references have been retained.
Page 13, line 7. Should be Fig. 5E (not 6E)?
This mistake was corrected
Legend to Fig. 1C. Lane numbers appear to be wrong. pE4Pin alone is in lane 3; and with pAATAV is in lane 2.
Legend to Fig. 2B . This mentions blotting using anti-TOR antibodies, but there are no such lanes in Fig. 2B .
In both cases, the mistakes have been corrected Thank you for submitting a new version of your manuscript, previously EMBOJ-2010-75339, as a new submission. Let me first of all apologise for the exceptionally long delay in getting back to you with a decision. Unfortunately, we experienced severe difficulties with the availability of the referees. Our original referee 3 was not available to look at the new version of the manuscript. We therefore asked our original referee 2 (now referee 1) to comment on his/her report and your reply. In addition we have involved a new referee (referee 2) to take a fresh look at the manuscript.
As you will see while both referees still have a number of issues with the evidence presented they would support publication here after appropriate revision. We should therefore be able to consider a revised manuscript in which the referees' comments are addressed in an adequate manner. This should include the point raised by referee 2 regarding direct evidence for the importance of RISP phosphorylation in re-initiation. I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Peer Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Editor
The authors have addressed my concerns by adding new data and/or modifying the text. I have no further comments.
comments on the reply to the report of the original referee 3:
In several places, especially for the sucrose density gradient/western blot analyses to study the distribution of components across different ribosome/subunit species, the authors should provide quantified data from multiple replicate experiments together with statistical analysis. This is important to support the authors' conclusions. The authors do not say how many experiments were done or how reproducible the data are. This comment applies to data in Figs. 5 and 6, where it is worrying that repetition of experiments seems to generate different data. It is crucial that the authors provide convincing evidence that the findings are robust an reproducible enough to fully support their conclusions.
The authors do not provide any new data to address the concern that the analysis in Fig. 3B does not provide evidence that the mRNA is intact, i.e., truly bicistronic. They also do not show the data showing that transactivation was not rescued by varying the amount of p35S TAV included in the assays.
Regarding the model shown in Fig. 7 , the authors have not prefaced their description of it with the caveats required by the reviewer. This may be due to some confusion: while the referee wrote that 'the model is not inconsistent with' the authors seem to have (mistakenly) assumed s/he meant 'not consistent with'.
The Discussion does not provide the cautionary description of the model that is appropriate here, which should emphasize what is clearly established and what is speculation requiring further work. The statement that this 'model provides further ideas for how to study the ... mechanism' is too vague. The authors mention that they include new data to support their conclusions but do not indicate where: is this Fig. 5F ? If so, the evidence that eIF3 still cosediments with 60S subunits (as claimed) is unconvincing.
This paper presents evidence that the plant reinitiation factor TAV interacts with, activates, and recruits to polysomes the protein kinase Tor, in a manner critically required for TAV stimulation of reinitiation, and possibly requiring Tor-mediated phosphorylation of the host factor RISP, which they implicated previously in reinitiation. The evidence for most of these assertions is strong, although not without a few weak points indicated below that would need to be rectified, but there seems to be no direct evidence that RISP phosphorylation is important for reinitiation, as they have not examined the effect of expressing a non-phosphorylatable, siRNA-resistant form of RISP in cells where endogenous RISP has been knocked down. Clearly, inclusion of such an experiment with positive results would greatly increase the scientific quality of the report. Without it, the mechanism of how Tor activates reinitiation would be up in the air; although the paper would still be a significant contribution in demonstrating recruitment of Tor to polysomes by TAV and a direct role for Tor in stimulating reinitiation and virus propagation, provided that the existing results on RISP phosphorylation were overinterpreted.
Specific comments:
-The results in Fig. 1E are important in showing that eliminating the Tor binding determinants in TAV impairs TAV function in virus replication; however, it needs to be shown that the TAV mutants are properly expressed. Presumably they are since a larger deletion of the dsR motif seems to be well-expressed in the input samples for the experiment in Fig. 2F ; but this point needs to be addressed explicitly.
-The results in Fig. 2D are critical in providing evidence that overexpression of TAV increases S6K1 phosphorylation, and that knock-down of Tor reduces S6K1-P levels in plant cells, leading to the conclusion that TAV overexpression is activating Tor phosphorylation of S6K1-P; however, the analysis would be more complete if they could show that Tor knockdown eliminates the increased level of S6K1-P that occurs in TAV overexpressing cells.
-It would also be useful to repeat the experiment in Fig. 2D comparing wt TAV to the del-dsR TAV mutant (incapable of binding Tor) to confirm that the activation of Tor (increase in S6K1-P level) in plant cells is dependent on TAV-Tor interaction via the dsR region. The data in Fig. 2E support this conclusion but involve in vitro phosphorylation of recombinant S6K1 in extracts as opposed to phosphorylation of endogenous S6K1 in cells.
-Several key experiments employ the plant cell line in which Tor is depleted by siRNA. One would like to see that the important effect of Tor knockdown in impairing reinitiation of the bicistronic reporter shown in Fig. 4D can be rescued by ectopic expression of an siRNA-resistant Tor construct.
-In Fig. 6E , yeast two-hybrid assays are used to provide evidence that RISP phosphorylation alters its interactions with eIF3c, TAV, and L24, by comparing the non-phosphorylatable S267A mutant to wt RISP. However, it's unclear why the authors believe that the wt RISP would get phosphorylated in yeast on S267, which would be required to justify their interpretations.
-As noted above, while the evidence shown in Fig. 6C , F is strong that RISP gets phosphorylated on S267 in polysomes in a manner dependent on TAV interaction with Tor, there is no direct evidence that this phosphorylation of RISP is important for reinitiation. This represents a significant weakness in the evidence supporting the model in Fig. 7 . It's also difficult to integrate the two-hybrid results in Fig. 6E (even if their interpretation of these data is justified) into the Fig. 7 Each sucrose gradient experiment presented in Figs 5 and 6 was performed a minimum of four times, where all repeats were reproducible. We now include information about experimental repeats in the legend of Fig 5. However, we believe that we can make only qualitative conclusions concerning these results. Also, it was clear that RISP-S267-P cosediments with fractions of polysomes in TAV-but not in TAV dsR transgenic plants in all repetitions carried out. Nevertheless, we appreciated the reasoning behind this request of referee 1 and we now provide quantification of sucrose gradients in Fig. 5G and H. Quantification data are provided as Supplementary data, see Supplementary Fig. 5 .
The authors do not provide any new data to address the concern that the analysis in Fig. 3B does not provide evidence that the mRNA is intact, i.e., truly bicistronic.
The bicistronic GUS RNA levels were controlled by RT-qPCR and the length of biGUS transcripts was verified by semi-quantitative reporter targeted PCR. The latter data is now also included. See, for example, Fig. 3B (bottom panel). biGUS is ìtruly bicistronicî ó it does not give rise to any significant GUS activity during 24h of protoplast incubation without TAV, in contrast to GFP, which is expressed from monocistronic RNA with or without TAV.
They also do not show the data showing that transactivation was not rescued by varying the amount of p35S TAV included in the assays.
These data are provided now as Supplementary Fig. S4A . Fig. 7 We completed the model description and improved the Discussion. Fig. 5F ? If so, the evidence that eIF3 still cosediments with 60S subunits (as claimed) is unconvincing.
Regarding the model shown in
The authors mention that they include new data to support their conclusions but do not indicate where: is this
Experiments showing the distribution of TAV and eIF3 between 60S and 40S ribosomal subunit fractions after EDTA-dependent dissociation of polysomes prepared from WT and and AT7 plants are presented as Fig. 5H Unfortunately, knockdown of both rispa and rispb genes proved lethal. However, we performed an experiment in Arabidopsis protoplasts to test directly the effect of transient expression of either RISP or its RISP-S267A mutant on TAV-mediated reinitiation.
In Fig. 6F , we now present results showing that the RISP S267A mutant has lost its capacity to support reinitiation.
Specific comments:
-The results in Fig. 1E Western blot analysis of TAV, KKF and NGP expression in protoplasts during viral amplification are now included in Fig. 1 as Fig. 1F .
The results in Fig. 2D TOR knockout is lethal, and thus it is a quite hard job to obtain a TOR silenced line (and difficult and time consuming to obtain TOR silencing in TAV expressing lines).
Another way to address this question would be to inhibit TOR kinase activity in TAV transgenic plants. We thus used a specific inhibitor of TOR, Torin-1, to down-regulate the TOR signalling pathway. These data are shown as Supplementary Fig. S2A . Indeed, inhibition of TOR function by Torin-1 eliminates the increased level of S6K1-P that occurs in TAV overexpressing plants -It would also be useful to repeat the experiment in Fig. 2D 
comparing wt TAV to the del-dsR TAV mutant (incapable of binding Tor) to confirm that the activation of Tor (increase in S6K1-P level) in plant cells is dependent on TAV-Tor interaction via the dsR region.
This experiment is presented in Fig. 6 as Fig. 6C -Several key experiments employ the plant cell line in which Tor is depleted by siRNA. One would like to see that the important effect of Tor knockdown in impairing reinitiation of the bicistronic reporter shown in Fig. 4D can be rescued by ectopic expression of an siRNA-resistant Tor construct.
We currently see no way to produce an siRNA resistant TOR construct (also the large size of TOR is not conducive to ectopic expression). However, it was possible transiently express high levels of TOR in protoplasts from TOR-deficient 35-7 plants (Fig. S4B) . In this case, transiently produced TOR complemented loss of reinitiation. We now present the results of this experiment as Supplementary Fig. S4B . Fig. 6E , yeast two-hybrid assays are used to provide evidence that RISP phosphorylation alters its interactions with eIF3c, TAV, and L24, by comparing the non-phosphorylatable S267A mutant to wt RISP. However, it's unclear why the authors believe that the wt RISP would get phosphorylated in yeast on S267, which would be required to justify their interpretations.
-In
The required control now is included in Fig. 6E (bottom panel) . Thank you for sending us your revised manuscript. Our original referees 1 and 2 have now seen it again. In general, the referees are now positive about publication of your paper here. Still, referee 2 feels that there is one issue that still need to be addressed (see below) before we can ultimately accept your manuscript. Referee 1 has one minor suggestion. I would therefore like to ask you to deal with the issues raised.
Furthermore, there are three remaining editorial issues that need further attention. Prior to acceptance of every paper we perform a final check for figures containing lanes of gels that are assembled from cropped lanes. While cropping and pasting may be considered acceptable practices in some cases (please see Rossner and Yamada, JCB 166, 11-15, 2004 ) there needs to be a proper indication in all cases where such processing has been performed according to our editorial policies. Please note that it is our standard procedure when images appear like they have been pasted together without proper indication (like a white space or a black line between) to ask for the original scans (for our records). In the case of the present submission there is a panel that does not meet these requirements: Supplementary figure S6. I therefore like to kindly ask you to include a suitably modified version of this figure in the amended manuscript. I would also like to ask you to explain in the figure legend that all lanes (of both panels) come from the same gel. Please be reminded that according to our editorial policies we need to see the original scans for the figure in question. Furthermore, I need to ask you to include the statistical details for figure 6E and 6F into the figure legend. In respect to the manuscript text I need to urge you to go through and modify the manuscript text (mainly part of the introduction and the first part of the results section) once more to avoid using exact phrases from your earlier publication (Thiebeauld et al. 2009; EMBO J. 28, 3171-84; PMID: 19745810) .
I am sorry to have to be insistent on this at this late stage. However, we feel that these final editorial amendments are in your as well as in the interest of our readers.
Thank you very much for your cooperation.
Editor
------------------------------------------------
The authors have responded to my concerns by providing additional data, quantifying earlier data and by modifying the text in various places.
Overall,I am satisfied that they have addressed my concerns.
There is just one, very minor, outstanding point -the panels in Fig. S5 should be labelled A and B not G and H.
I appreciate the many new experiments the authors performed to address all of my comments on the previous version, which largely improved the scientific quality of the work. However, the key new experiment in Fig. 6F , showing that nonphosphorylatable RISP-S267A is defective in stimulating reinitiation, seems to be flawed by the fact that there is a much larger level of TAV present in lane 4 than in lane 3, making it unclear whether the increase in reinitiation (biGUS expression) seen for the lane 4 cells is promoted by the ectopic expression of phosphorylatable RISP or by the higher TAV level that seems to occur in these transfectants. (The TAV level in lane 4 is even higher than it appears in the blot shown in the top strip if one normalizes for the loading control on the bottom strip.) Presumably, the experiment needs to be repeated to eliminate this caveat to their interpretation.
2nd Revision -authors' response 24 January 2011
Referee 1. In addition to the changes already made, panels G and H were exchanged with A and B in Fig. S5 .
Referee 2. We repeated the experiment shown in Fig. 6F to prove that the failure of mutant RISP to increase the level of TAV-mediated transactivation is not due to low TAV concentration in those protoplasts compared to protoplasts expressing wild type RISP. Now, it is clear that the level of TAV expression is similar in samples with RISP and mutant RISP, but mutant RISP is not active. Concerning the remaining editorial issues (1) we have provided the original scans (the Coomassiestained gel and its autoradiograph) for Supplementary Fig. S6 . You will see that we moved two slots from one end of the gel to the other. (2) We now include statistical information in the legends to Figs 6E and 6F; (3) We have done our best to remove phrases that appeared in our previous publication (ThiÈbeauld et al., 2009 ).
I hope that this version is now acceptable for publication in EMBO J.
